Press release
Relapsed/refractory acute myeloid leukemia (AML) Pipeline 2025: Pioneering Clinical Developments by 50+ Global Leaders - DelveInsight | Featuring Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxin
Relapsed/refractory acute myeloid leukemia Pipeline 2025
With relapsed/refractory acute myeloid leukemia (AML) becoming increasingly prevalent worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and other cancers, there is a rising need for safer and more effective therapies. According to DelveInsight, the AML pipeline includes 50+ pharmaceutical and biotech companies actively developing over 75 therapeutic candidates targeting relapsed/refractory AML. These candidates span multiple stages of clinical and preclinical development, highlighting the strong innovation and commitment to tackling this critical healthcare challenge.
DelveInsight's "Relapsed/refractory Acute Myeloid Leukemia (AML) Pipeline Insight 2025" report provides a comprehensive and strategic assessment of the R&D landscape. It covers clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving AML therapeutics market and the innovations shaping its future.
Explore the Cutting-Edge Landscape of Relapsed/refractory acute myeloid leukemia (AML) Drug Development @ https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Relapsed/refractory acute myeloid leukemia (AML) Pipeline Report
*
DelveInsight's Relapsed/refractory acute myeloid leukemia (AML) pipeline report highlights a dynamic landscape with 50+ active companies developing over 75 therapeutic candidates for the treatment of relapsed/refractory AML.
*
In May 2025, ARCE Therapeutics Inc. initiated a study evaluating ARD103, a CAR-T therapy targeting C-type lectin-like molecule-1 (CLL-1). CLL-1 is highly expressed on myeloid blasts and leukemia stem cells (LSCs) but not on healthy hematopoietic stem cells, making it a promising therapeutic target for AML and other myeloid malignancies.
*
In the same month, Vor Biopharma launched a Phase 1/2 trial of VCAR33, a donor-derived anti-CD33 CAR-T therapy, in patients with relapsed or refractory AML after HLA-matched allogeneic stem cell transplantation.
*
Also in May 2025, Apollo Therapeutics Ltd began a Phase 1/2 trial assessing the safety and efficacy of APL-4098, administered alone or in combination with azacitidine, in patients with relapsed/refractory AML, MDS/AML, and MDS with excess blasts (EB). The Phase 1 portion is limited to patients with the MDS-EB subtype.
*
Key companies developing treatments for relapsed/refractory AML include Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
*
Promising pipeline therapies under development include APG-2575, CLN 049, Lanraplenib, and additional candidates in various clinical stages.
Relapsed/refractory acute myeloid leukemia (AML) Overview:
Relapsed/refractory acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis and limited therapeutic options. Its symptoms-such as fatigue, weakness, shortness of breath, and weight loss-are often vague and can mimic less serious conditions, resulting from anemia and decreased production of healthy blood cells. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the most effective treatment for eligible patients, but it carries significant risks and is not suitable for everyone. Despite these challenges, recent advances, including targeted therapies, are providing additional options that may offer fewer side effects and longer periods of remission. Treatment decisions are highly individualized, taking into account factors such as patient age, overall health, genetic profiles, prior therapies, and timing of relapse.
Download the Relapsed/refractory acute myeloid leukemia (AML) sample report to know in detail about the Relapsed/refractory acute myeloid leukemia (AML) treatment market @ https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Relapsed/refractory acute myeloid leukemia (AML) Pipeline Analysis
The Relapsed/refractory acute myeloid leukemia (AML) pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Relapsed/refractory acute myeloid leukemia (AML) Market.
*
Categorizes Relapsed/refractory acute myeloid leukemia (AML) therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Relapsed/refractory acute myeloid leukemia (AML) drugs under development based on:
*
Stage of development
*
Relapsed/refractory acute myeloid leukemia (AML) Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Relapsed/refractory acute myeloid leukemia (AML) Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Relapsed/refractory acute myeloid leukemia (AML) Licensing agreements
*
Funding and investment activities supporting future Relapsed/refractory acute myeloid leukemia (AML) market advancement.
Unlock key insights into emerging Relapsed/refractory acute myeloid leukemia (AML) therapies and market strategies here: https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs
APG-2575: Ascentage Pharma
APG-2575, developed by Ascentage Pharma, is an oral, selective Bcl-2 inhibitor designed to block the Bcl-2 protein and trigger apoptosis in cancer cells, promoting their destruction. It is the first Bcl-2 selective inhibitor from China to enter clinical trials. The U.S. FDA has granted APG-2575 orphan drug designation for five indications: refractory chronic lymphocytic leukemia (CLL), multiple myeloma, Waldenstrom macroglobulinemia, acute myeloid leukemia, and follicular lymphoma.
CLN 049: Cullinan Oncology
CLN-049 (Florentine) is a humanized bispecific T cell-engaging antibody being developed for acute myeloid leukemia (AML). It binds to FLT3 on leukemia cells and CD3 on T cells, prompting T cells to kill cancer cells via their natural cytotoxic activity. Unlike other AML targets such as CD33 and CD123, FLT3 is frequently expressed on AML cells but rarely on healthy blood cells, offering a more selective approach. Preclinical studies have demonstrated potent, specific AML cell killing and enhanced survival in mouse models. A Phase I trial is currently ongoing in patients with relapsed or refractory AML or myelodysplastic syndromes (MDS).
Lanraplenib: Kronos Bio
Lanraplenib is a next-generation SYK inhibitor originally investigated for autoimmune disorders. Preclinical research has shown its anti-leukemic activity in AML samples harboring NPM1 and FLT3 mutations. It is currently being developed for patients with relapsed or refractory FLT3-mutated AML, as well as for newly diagnosed patients with NPM1 and/or FLT3 mutations who are aged over 75 or are unsuitable for intensive induction chemotherapy.
Relapsed/refractory acute myeloid leukemia (AML) Pipeline Therapeutic Assessment
Relapsed/refractory acute myeloid leukemia (AML) Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Relapsed/refractory acute myeloid leukemia (AML) By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Relapsed/refractory acute myeloid leukemia (AML) Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Relapsed/refractory acute myeloid leukemia (AML) Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Relapsed/refractory acute myeloid leukemia (AML) therapies and key Relapsed/refractory acute myeloid leukemia (AML) companies [https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Relapsed/refractory acute myeloid leukemia (AML) Current Treatment Patterns
4. Relapsed/refractory acute myeloid leukemia (AML) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Relapsed/refractory acute myeloid leukemia (AML) Late-Stage Products (Phase-III)
7. Relapsed/refractory acute myeloid leukemia (AML) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsed/refractory acute myeloid leukemia (AML) Discontinued Products
13. Relapsed/refractory acute myeloid leukemia (AML) Product Profiles
14. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
15. Relapsed/refractory acute myeloid leukemia (AML) Key Products
16. Dormant and Discontinued Products
17. Relapsed/refractory acute myeloid leukemia (AML) Unmet Needs
18. Relapsed/refractory acute myeloid leukemia (AML) Future Perspectives
19. Relapsed/refractory acute myeloid leukemia (AML) Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Relapsed/refractory acute myeloid leukemia (AML) pipeline reports offerings [https://www.delveinsight.com/report-store/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=relapsedrefractory-acute-myeloid-leukemia-aml-pipeline-2025-pioneering-clinical-developments-by-50-global-leaders-delveinsight-featuring-ascentage-pharma-cullinan-oncology-kronos-bio-maxin]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/refractory acute myeloid leukemia (AML) Pipeline 2025: Pioneering Clinical Developments by 50+ Global Leaders - DelveInsight | Featuring Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxin here
News-ID: 4202742 • Views: …
More Releases from ABNewswire
C-MET Metastatic NSCLC Market: Epidemiology, Therapies, Companies, DelveInsight …
In 2023, the US accounted for the maximum share of the total C-MET Metastatic NSCLC Market in the 7MM, i.e., approximately 75%.
Emerging C-MET Metastatic NSCLC therapies-such as TABRECTA, TEPMETKO, Telisotuzumab Vedotin, REGN5093, REGN5093-M114, APL-101, MYTX-011, Glumetinib, Amivantamab, and Capmatinib Combination Therapy-are expected to drive growth in the C-MET Metastatic NSCLC market in the coming years.
DelveInsight has published a new report titled "C-MET Metastatic NSCLC - Market Insights, Epidemiology, and Market…
Pancreatic Ductal Adenocarcinoma Pipeline 2025: Pioneering Clinical Developments …
Key companies in pancreatic ductal adenocarcinoma market include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics.
With Pancreatic Ductal Adenocarcinoma (PDAC) reaching epidemic levels globally and contributing to comorbidities such as diabetes, cardiovascular disease, and other cancers, there is an increasing demand for safer and more effective therapies. According to DelveInsight, the…
Metastatic Renal Cell Carcinoma Pipeline 2025: Pioneering Clinical Developments …
Key companies in the metastatic renal cell carcinoma pipeline include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Nanobiotix, Aravive, Mirati Therapeutics, BeiGene, Shanghai PerHum Therapeutics, Akeso Biopharma, NeoTX Therapeutics Ltd., and others.
With metastatic renal cell carcinoma (mRCC) reaching epidemic levels worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and other cancers, there…
Oligometastatic Disease Market: Epidemiology, Therapies, Companies | DelveInsigh …
According to DelveInsight's patient-based forecasting model, the oligometastatic disease market size in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-2034), owing to an increase in the cases and the launch of new therapies.
Emerging therapies such as IMSA101, PNT2002 (177Lu-PNT2002), and others are expected to drive growth in the Oligometastatic Disease market in the coming years.
DelveInsight has released a…
More Releases for AML
Top Trends Transforming the Hemato Oncology Testing Market Landscape in 2025: Ne …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Hemato Oncology Testing Industry Market Size Be by 2025?
There has been a swift expansion in the hemato oncology testing market in the past few years. The market, which was valued at $3.5 billion in 2024, is predicted to surge to $3.96 billion in 2025, reflecting…
AML BitCoin Founder Asks President Trump to release their AML BITCOIN Classified …
The DOJ and the FBI should practice tough love while also providing financial incentives for government employees that uphold the constitution and obey the law. AG Bondi and Director Patel should ask President Trump for access to some of the billions of dollars that DOGE has saved us and utilize it for pay raises. Their employees need to be taken care of financially, or their hardships will make them the…
Anti-Money Laundering (AML) Software Market Is Booming So Rapidly with Thomson R …
The Latest published market study on Global Anti-Money Laundering (AML) Software Market provides an overview of the current market dynamics in the Anti-Money Laundering (AML) Software space, as well as what our survey respondents all outsourcing decision-makers predict the market will look like in 2032. The study breaks the market by revenue and volume (wherever applicable) and price history to estimate the size and trend analysis and identify gaps and…
Global Anti Money Laundering (AML) Software Market Size, Share and Forecast By K …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the Market Research Intellect, the global Anti Money Laundering (AML) Software market is projected to grow at a robust compound annual growth rate (CAGR) of 14.78% from 2024 to 2031. Starting with a valuation of 7.83 Billion in 2024, the market is expected to reach approximately 17.9 Billion by 2031, driven by factors such as Anti Money Laundering (AML) Software and Anti Money Laundering (AML)…
What is AML Verification? A Detailed Guide
With the rise of cryptocurrencies and the increasing adoption of digital assets, regulatory frameworks have become a critical component for ensuring that the cryptocurrency space remains secure and compliant. One of the most important elements in this regulatory framework is AML verification, which stands for Anti-Money Laundering.
Image: https://revbit.net/wp-content/uploads/2024/10/aml-in-crypto-3-1024x640.png
What is AML Verification?
AML (Anti-Money Laundering) verification [https://revbit.net/] refers to a set of procedures and regulations designed to prevent illegal activities such as…
IventiumPro.io Adheres to Strict KYC and AML Regulations
London, United Kingdom - IventiumPro.io [http://iventiumpro.io], a company that provides a reliable financial services, is committed to maintaining high standards of regulatory compliance. The company follows Know Your Customer (KYC) and Anti-Money Laundering (AML) regulations to ensure the integrity and security of its operations. This adherence reflects a strong dedication to preventing illegal activities and protecting the financial system.
KYC regulations are designed to verify the identity of clients. IventiumPro.io collects…
